PridCor Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PridCor Therapeutics is a private, pre-revenue biotech startup leveraging decades of founder experience to tackle poorly understood chronic illnesses. Its core strategy involves a fixed-dose combination therapy designed to suppress latent viral reactivation and reduce inflammation, initially targeting Long COVID. The company is also developing a proprietary throat spray for pharyngitis and a 3D-printed surgical device, positioning itself at the intersection of drug repurposing and specialized medical technology. A key clinical collaboration with Mount Sinai Hospital aims to validate its lead therapeutic approach.

Infectious DiseaseImmunologyNeurologyGastroenterologyPain

Technology Platform

Clinical insight-driven platform focused on rational combination of approved drugs (antiviral + anti-inflammatory) to target latent viral reactivation and chronic inflammation in post-viral syndromes.

Opportunities

The massive, unmet need in Long COVID, affecting an estimated 20 million Americans, presents an immediate and urgent market with significant government and clinical focus.

Success in Long COVID could serve as a powerful proof-of-concept for applying the same therapeutic approach to other large, underserved chronic condition markets like Fibromyalgia and ME/CFS.

The drug repurposing strategy may allow for a faster and less costly development path compared to novel drug discovery.

Risk Factors

High clinical risk as the core viral reactivation hypothesis for these syndromes is not yet proven, and combination trials may fail.

The company is pre-revenue and private, with undisclosed funding, creating substantial financial and operational risk for advancing costly clinical trials.

The competitive landscape for Long COVID is intensifying rapidly with larger, well-resourced entities, creating commercial and scientific competition.

Competitive Landscape

The Long COVID and chronic syndrome space is becoming increasingly competitive, with large pharma (e.g., Pfizer, AstraZeneca) and numerous biotech startups exploring various mechanisms, including antiviral, immunomodulatory, and autonomic nervous system therapies. PridCor's primary differentiation is its specific focus on the herpesvirus reactivation/inflammation hypothesis and its use of a repurposed drug combination. It faces competition from both novel drug developers and other repurposing efforts.

More companies in Drug Delivery & Formulation →More companies in United States →